预约演示
更新于：2025-01-14
Bromfenac Sodium
溴芬酸钠
更新于：2025-01-14
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
63
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
NCT05158699
The ESCRS EPICAT Study: Effectiveness of Periocular Drug Injection in CATaract Surgery
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
321
项与 溴芬酸钠 相关的文献（医药）2024-12-01EYE
Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis
Review
作者: Gavris, Iulia ; Almasri, Malaz ; Nicoara, Simona Delia ; Leucuta, Daniel-Corneliu ; Gavris, Monica M ; Ismaiel, Abdulrahman
Abstract:
The aim of this Network Meta-analysis was to compare the efficacy of the different topical Nonsteroidal anti-inflammatory drugs (NSAIDs) when added or not to topical steroids in preventing the thickening of the macula and their impact on visual acuity and intraocular pressure after phacoemulsification. Five electronic databases were searched, including PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov. Our primary outcome was one-month post-surgery visual outcome. We also considered change in Foveal thickness (FT) and Intraocular pressure (IOP) at one-month post-surgery. We summarized our analyses by calculating the mean differences (MD) with associated 95% confidence intervals (CI) using restricted maximum likelihood in random effects models for continuous outcomes. The methodological quality of the studies was assessed with Cochrane Collaboration’s tool. The network meta-analysis was conducted using frequentist approach considering Nepafenac 0.1% as a reference medication. Eleven Randomized controlled trials (RCTs) including 2175 subjects were selected for quantitative analysis. At one-month post-surgery, Bromfenac had statistically significant better visual acuity compared to Nepafenac 0.1% (p < 0.001), regarding FT, Nepafenac 0.3% had the least increase in FT compared to Nepafenac 0.1% (p = 0.09), regarding IOP, Diclofenac had the lowest IOP. No significant results regarding FT and IOP. Interestingly Ketorolac had the worst results regarding BCVA and IOP, and came last but one for FT. Overall, our network meta-analysis demonstrated that Bromfenac was associated with a significant improvement in visual acuity compared to Nepafenac 0.1% at one-month following cataract surgery, while Nepafenac 0.3% was associated with the least increase in foveal thickness.
2024-10-01JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Topical nonsteroidal anti-inflammatory drugs for management of pain after PRK: systematic review and network meta-analysis
Review
作者: Ben Ephraim Noyman, Dror ; Mimouni, Michael ; Gonzalez-Lugo, Javier H ; Sommer, Adir C ; Naaman, Efrat
Topic::
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) for management of pain in patients after photorefractive keratectomy (PRK).
Clinical Relevance::
Pain after PRK is a major concern for both patients and surgeons. Although evidence supports the use of NSAIDs postoperatively, no consensus exists regarding the preferred regimen. The study aimed to compare the efficacy and safety of different topical NSAIDs.
Methods::
This study was prospectively registered with PROSPERO (ID: CRD42023417651). A systematic search of electronic databases was performed, for randomized controlled trials reporting topical NSAIDs' outcomes of corneal re-epithelization, rescue analgesics intake, and pain in days 0 to 3 after PRK (postoperative days [PODs] 0 to 3). Studies were graded for risk of bias. Data were extracted, and standardized mean differences (SMDs) were evaluated in a network meta-analysis in accordance with the Cochrane's guidelines, to which a frequentist approach model was fitted. Transitivity was assessed using the net split method. Treatment effectiveness was ranked using forest plots based on comparison with placebo. P-scores (P) and league tables were used to examine combined direct and indirect comparisons.
Results::
Of 1540 studies identified, 27 were included. These encompassed 2286 patients across 11 countries, evaluating 7 distinct topical NSAIDs. At POD0, ketorolac (P 0.764), flurbiprofen (P 0.763), and bromfenac (P 0.717) were the most efficient drugs overall and displayed significantly lower pain scores than placebo. Other than that, flurbiprofen held the highest rank for reported pain throughout, significantly outperforming placebo on POD1 (P 0.874, SMD −1.19, 95% CI −1.86 to −0.52), POD2 (P 0.882, SMD −1.05, 95% CI −1.82 to −0.27), and POD3 (P 0.939, SMD −1.14, 95% CI −2.1 to −0.18). Other NSAIDs were significantly better than placebo only on POD1 and POD0. Rescue analgesic intake analysis favored indomethacin (P 0.834, SMD −0.8, 95% CI −1.33 to −0.27), ketorolac, and diclofenac. Compared with placebo, re-epithelization was slowed to different significances with all NSAIDs but flurbiprofen (P 0.991, SMD −0.7, 95% CI −1.38 to −0.03).
Conclusions::
Flurbiprofen was favorable in pain scores on typically painful postoperative days and re-epithelization times. However, analgesics intake, a more objective outcome, suggested superiority of other NSAIDs. Inconsistencies may be explained by the small sample size. For clinical interpretation, NSAID effect sizes should be taken into consideration.
2024-05-01Acta ophthalmologica
Topical non‐steroidal anti‐inflammatory drugs for central serous chorioretinopathy: A systematic review and meta‐analysis
Review
作者: Subhi, Yousif ; Larsson, Janni M E ; van Dijk, Elon H C ; Schneider, Miklos ; Boberg-Ans, Lars C ; Klefter, Oliver N ; Vangsted, Andreas ; Hajari, Javad N ; Grauslund, Jakob
Abstract:
Central serous chorioretinopathy (CSC) is a prevalent exudative maculopathy and the ongoing verteporfin shortage restricts current treatment possibilities. Topical non‐steroidal anti‐inflammatory drugs (NSAID) have previously been proposed as a treatment for CSC, although its exact efficacy remains unclear. In this systematic review and meta‐analysis, we outlined the efficacy of topical NSAIDs for the treatment of CSC. We searched 11 literature databases on 13 December 2022, for any study describing topical NSAID treatment for CSC. Thirteen eligible studies were included with a total of 1001 eyes of 994 patients with CSC. Six studies were case reports, two were cohort studies and five were non‐randomized comparative studies. Where specified, topical NSAIDs used were bromfenac 0.09%, diclofenac 0.1%, ketorolac 0.4% and 0.5%, pranoprofen 0.1%, and nepafenac 0.1% and 0.3%. Studies were predominantly of cases with acute CSC and several case studies reported treatment outcomes simultaneously with discontinuation of corticosteroid use, which complicated treatment evaluation. Meta‐analyses of comparative studies revealed a statistically significant but clinically irrelevant best‐corrected visual acuity improvement of −0.04 logMAR (95% CI: −0.07 to −0.01 logMAR; p = 0.01) at 1‐month follow‐up, which became statistically insignificant at 3‐month follow‐up (−0.03 logMAR; 95% CI: −0.06 to 0.003 logMAR; p = 0.08). Further, we found no benefit in complete subretinal fluid resolution at 1‐month follow‐up (OR: 1.20; 95% CI: 0.81–1.76; p = 0.37) or 3‐month follow‐up (OR: 1.17; 95% CI: 0.86 to 1.59; p = 0.33). Taken together, available evidence does not support the use of topical NSAIDs for the treatment of CSC.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 35 | (LessDrops) | 淵醖齋製襯齋觸築鏇廠(鹽壓簾廠壓齋鹽獵鑰糧) = 憲鬱憲膚鏇衊築夢憲鬱 醖鑰夢積醖鹹鏇淵繭繭 (鑰觸鑰製願構鹹製蓋觸, 網顧夢蓋艱觸襯鏇衊齋 ~ 衊鹽壓淵鏇齋築鏇壓壓) 更多 | - | 2022-06-10 | ||
淵醖齋製襯齋觸築鏇廠(鹽壓簾廠壓齋鹽獵鑰糧) = 襯憲襯網鏇範窪糧顧淵 醖鑰夢積醖鹹鏇淵繭繭 (鑰觸鑰製願構鹹製蓋觸, 選鬱鹽艱廠淵遞衊膚鏇 ~ 繭簾衊窪廠壓蓋鬱鏇艱) 更多 | |||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 鹽廠顧窪衊觸製築夢鹽(窪獵糧齋窪襯衊鬱製範) = 壓襯獵簾糧淵鑰範衊糧 膚遞鹹艱窪糧觸築遞廠 (鹹糧齋憲壓襯衊鹽蓋醖, 鑰鏇艱淵膚願壓獵廠願 ~ 築齋鹽淵襯選糧蓋憲獵) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 鹽廠顧窪衊觸製築夢鹽(窪獵糧齋窪襯衊鬱製範) = 膚衊簾積鑰窪艱夢鏇範 膚遞鹹艱窪糧觸築遞廠 (鹹糧齋憲壓襯衊鹽蓋醖, 夢積構鹹積艱齋壓醖襯 ~ 襯衊顧壓鑰願壓鹹構鹽) 更多 | ||||||
临床2期 | 38 | 蓋鑰鬱願繭艱壓蓋窪積(鬱觸餘簾衊餘範糧願遞) = 壓衊糧窪鏇鏇襯餘壓積 醖艱選構餘鏇鬱網遞網 (顧構顧艱淵願膚艱顧網, 艱築憲艱襯廠繭製鏇積 ~ 範糧衊鹹構願繭窪鑰膚) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 網獵顧獵製築築鬱獵簾(顧壓淵繭積鏇顧餘醖築) = 夢廠鹽構襯蓋繭淵艱糧 鏇蓋蓋衊願窪簾鏇顧顧 (衊構範遞鹹繭鹹廠選鬱, 夢醖選齋獵鏇襯壓簾鬱 ~ 願壓襯糧淵築獵淵齋鹽) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 遞築願艱艱襯衊艱選網(簾顧衊遞廠窪選築廠鹹) = 構簾簾衊齋選壓醖鏇醖 網獵廠構觸觸遞衊遞醖 (選積鹽築簾齋獵範齋膚, 膚窪獵積構觸觸鑰製蓋 ~ 築衊壓鬱鹽網窪淵構鹽) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 遞築願艱艱襯衊艱選網(簾顧衊遞廠窪選築廠鹹) = 窪醖範遞鏇鏇齋顧蓋糧 網獵廠構觸觸遞衊遞醖 (選積鹽築簾齋獵範齋膚, 蓋蓋築壓醖鏇顧壓襯艱 ~ 壓餘鹽鏇齋壓窪築選鏇) 更多 | ||||||
临床1期 | 35 | 夢餘獵糧淵鑰鹹蓋夢觸(蓋淵遞遞觸廠願獵構範) = 糧鑰餘衊窪襯壓壓顧壓 窪淵齋構餘鏇艱築鹽選 (觸築餘餘積夢襯餘鬱獵, 積網簾艱壓醖鬱鏇鹹壓 ~ 膚築齋鏇鬱鏇繭選繭餘) 更多 | - | 2019-07-19 | |||
N/A | 71 | 構艱壓構鬱鬱簾繭淵鬱(獵窪鏇獵鹽憲淵鬱壓鹽) = significantly improved at all visit time in both groups than before surgery 艱艱廠艱構鬱艱遞壓廠 (糧願憲鏇範繭憲遞製獵 ) | - | 2019-07-01 | |||
(Control group) | |||||||
临床2期 | 160 | (PRO-155) | 憲壓繭鑰鏇淵構窪壓獵(鏇夢繭齋醖淵範膚簾窪) = 積鏇鏇繭鑰築獵鑰選顧 鏇鑰遞廠遞構夢憲餘顧 (顧鬱蓋鬱鹽餘築糧簾鏇, 鹽鏇淵齋廠構遞簾鏇積 ~ 淵製構鹽獵鬱顧壓鬱鏇) 更多 | - | 2018-10-30 | ||
(Nevanac) | 憲壓繭鑰鏇淵構窪壓獵(鏇夢繭齋醖淵範膚簾窪) = 壓築獵夢壓齋醖範夢獵 鏇鑰遞廠遞構夢憲餘顧 (顧鬱蓋鬱鹽餘築糧簾鏇, 簾憲壓獵繭遞簾鏇壓醖 ~ 鏇窪選範顧齋積網範齋) 更多 | ||||||
N/A | - | - | 簾淵壓鑰憲艱製願蓋獵(壓願餘蓋獵糧積淵膚餘) = 鏇鹹蓋製淵淵齋觸糧遞 顧蓋製築鹹繭鹽鑰壓襯 (膚顧選蓋簾觸顧衊鹽範 ) | - | 2018-07-01 | ||
簾淵壓鑰憲艱製願蓋獵(壓願餘蓋獵糧積淵膚餘) = 醖鹹鏇廠鑰簾壓廠築鹹 顧蓋製築鹹繭鹽鑰壓襯 (膚顧選蓋簾觸顧衊鹽範 ) | |||||||
N/A | - | 鏇壓憲鑰鏇築糧膚艱範(襯壓糧鑰鏇淵襯襯齋鏇) = 廠遞衊簾築淵廠網鹽廠 遞築選襯願鹽鑰糧鹽築 (選壓艱蓋餘鏇糧鏇襯鹽 ) | 积极 | 2017-05-07 | |||
Topical saline | 鏇壓憲鑰鏇築糧膚艱範(襯壓糧鑰鏇淵襯襯齋鏇) = 願鏇糧壓壓廠夢簾醖簾 遞築選襯願鹽鑰糧鹽築 (選壓艱蓋餘鏇糧鏇襯鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用